Greenwood Capital Associates LLC Acquires 4,419 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Greenwood Capital Associates LLC raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 52.3% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,861 shares of the biopharmaceutical company’s stock after buying an additional 4,419 shares during the period. Greenwood Capital Associates LLC’s holdings in Regeneron Pharmaceuticals were worth $6,752,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. E Fund Management Hong Kong Co. Ltd. raised its stake in Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 31 shares during the period. Activest Wealth Management raised its stake in Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 21 shares during the period. Costello Asset Management INC bought a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $27,000. Saudi Central Bank bought a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $27,000. Finally, Curat Global LLC bought a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $32,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.0%

Shares of REGN stock opened at $600.00 on Friday. The stock’s fifty day moving average price is $571.38 and its two-hundred day moving average price is $568.39. The company has a market cap of $63.59 billion, a PE ratio of 15.12, a P/E/G ratio of 1.92 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,038.81. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company’s revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the business posted $11.56 EPS. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.87%.

Analysts Set New Price Targets

REGN has been the topic of a number of recent research reports. Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. JPMorgan Chase & Co. lowered their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating on the stock in a research note on Monday, June 9th. Jefferies Financial Group increased their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research note on Wednesday, August 27th. Canaccord Genuity Group reiterated a “buy” rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Finally, Guggenheim increased their target price on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.